Your browser doesn't support javascript.
Cytosponge as a risk stratification tool in patients overdue barrett’s surveillance due to Covid-19
Gut ; 70(Suppl 4):A34, 2021.
Article in English | ProQuest Central | ID: covidwho-1504739
ABSTRACT
HFR-1 Table 1Demographics, baseline Barrett’s baseline information and outcome of all patients who have completed the Cytosponge ® procedure. * 2 patients still awaiting endoscopic assessment. NDBE Non-Dysplastic Barrett’s Oesophagus, INDEF Indefinite for dysplasia, LGD Low-Grade Dysplasia, IMC intramucosal adenocarcinoma TFF3 - Atypia - P53 - TFF3 + Atypia - P53 - TFF3 -/+ Atypia + P53 - TFF3 + Atypia + P53 + Number of patients 14 26 12 4 MF 12 2 20 6 11 1 4 0 Median maximal BE length (cm) 2.5 5 5 6 Triage decision Repeat Cytosponge®/endoscopy within 24 months Endoscopy in 12 months Endoscopy within 3 months Endoscopy within 3 months Endoscopy and histology findings - - NDBE 5 ATYPIA 1 INDEF 2 LGD 2 NDBE 1 LGD 2 IMC 1 ConclusionsThe Cytosponge® has proved to be an acceptable non-endoscopic tool for patients with BE under surveillance where endoscopy is not possible. Preliminary data are promising to detect dysplasia and triage patients to endoscopy early. Further large scale, longitudinal follow-up is needed.

Full text: Available Collection: Databases of international organizations Database: ProQuest Central Type of study: Etiology study / Prognostic study / Risk factors / Screening study Language: English Journal: Gut Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: ProQuest Central Type of study: Etiology study / Prognostic study / Risk factors / Screening study Language: English Journal: Gut Year: 2021 Document Type: Article